DC Circ. Boosts Teva In Row With FDA Over Merck Drugs

By Erin Marie Daly

Law360, New York (March 02, 2010, 7:09 PM ET) -- Teva Pharmaceutical Industries Ltd. has been given a renewed shot at the market for hypertension drugs, with a federal appeals court granting the Israeli drugmaker 180 days to exclusively sell its generic versions of Merck & Co.'s popular losartan potassium products Hyzaar and Cozaar.

In a ruling Tuesday, the U.S. Court of Appeals for the District of Columbia Circuit overturned a lower court's decision that Teva had forfeited its exclusivity rights, agreeing with Teva that it should be entitled to the six-month period.

The case marks...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles